Novel antisense oligonucleotide shows disease-modifying potential in Dravet syndrome
21 Mar 2026
byJairia Dela Cruz
In children with Dravet syndrome, treatment with the investigational antisense oligonucleotide zorevunersen appears safe and efficacious, with seizure frequency reductions of up to 90 percent and improvements in nonseizure symptoms, according to two phase 1–2a studies (MONARCH and ADMIRAL) and the corresponding open-label extension studies (SWALLOWTAIL and LONGWING).